Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 12/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 4/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799040 | 0.86 | KMT2A (0.56) | KMT2AMEN1MAOBNPC1ALDH1A1 | |
| SCHEMBL132082 | 0.84 | AKR1C3 (0.63) | KMT2ANPC1RAB9A | |
| SCHEMBL25620248 | 0.83 | MEN1 (0.71) | KMT2AMEN1MAOBNPC1ALDH1A1 | |
| SCHEMBL177641 | 0.83 | SMN1; SMN2 (0.55) | KMT2AMEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL191052 | 0.82 | PARP1 (0.65) | KMT2AMEN1CES2CES1L3MBTL1 | |
| SCHEMBL177413 | 0.82 | F10 (0.48) | KMT2AMEN1MAOBALDH1A1MAOA | |
| SCHEMBL190231 | 0.82 | HDAC8 (0.56) | KMT2AMEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL52445 | 0.82 | CES2 (0.74) | KMT2AMEN1MAOBNPC1ALDH1A1 | |
| SCHEMBL28126653 | 0.82 | CES2 (0.74) | KMT2AMEN1MAOBNPC1ALDH1A1 | |
| SCHEMBL29589944 | 0.82 | CES2 (0.74) | KMT2AMEN1MAOBNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11876137-B2 | Field-effect transistor including a metal oxide composite protective layer, and display element, image display device, and system including the field-effect transistor | RICOH COMPANY, LTD. (JP) | 2024-01-16 | — | — | US | claimed |
| US-20200083383-A1 | FIELD-EFFECT TRANSISTOR INCLUDING A METAL OXIDE COMPOSITE PROTECTIVE LAYER, AND DISPLAY ELEMENT, IMAGE DISPLAY DEVICE, AND SYSTEM INCLUDING THE FIELD-EFFECT TRANSISTOR | RICOH COMPANY, LTD. (JP) | 2020-03-12 | — | — | US | claimed |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250257049-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2025-08-14 | — | — | US | disclosed |
| CN-111148744-B | Novel heterocyclic compounds as MGLUR7 modulators | 布拉格玛治疗公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20250002519-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | UNIV YALE (US) | 2025-01-02 | — | — | US | disclosed |
| CN-113645971-B | Compounds and uses thereof | 福宏治疗公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240293559-A1 | SHP2 inhibitor, pharmaceutical composition containing the same and application thereof | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2024-09-05 | — | — | US | disclosed |
| US-12071445-B2 | Precatalyst scaffolds for cross-coupling reactions, and methods of making and using same | YALE UNIVERSITY (US) | 2024-08-27 | — | — | US | disclosed |
| EP-4417600-A1 | SHP2 INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2024-08-21 | — | — | EP | disclosed |
| WO-2003048164-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-1283209-A1 | NOVEL BENZOTHIOPHENE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-02-12 | — | — | EP | disclosed |
| WO-2002098848-A1 | BENZOYLSULFONAMIDES AND SULFONYLBENZAMIDINES FOR USE AS ANTITUMOUR AGENTS | ELI LILLY AND COMPANY (US) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002057273-A9 | SERINE PROTEASE INHIBITORS COMPRISING A HYDROGEN-BOND ACCEPTOR | TRIGEN LTD (GB) | 2002-11-28 | — | — | WO | disclosed |
| US-20020156295-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | NATIONAL SCIENCE FOUNDATION | 2002-10-24 | — | — | US | disclosed |
| WO-2002057273-A1 | SERINE PROTEASE INHIBITORS COMPRISING A HYDROGEN-BOND ACCEPTOR | TRIGEN LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| US-6307087-B1 | USE OF CATALYSTS COMPRISING THESE LIGANDS IN TRANSITION METAL-CATALYZED CARBON-HETEROATOM AND CARBON-CARBON BOND-FORMING REACTIONS. | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2001-10-23 | — | — | US | disclosed |
| EP-1097158-A2 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000002887-A2 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002519-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | TIMCC, YAP1, TET2 | KMT2A 1431/4885MEN1 938/4885MAOB 3234/4885 |
| US-20250257049-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM2 | KMT2A 2063/4885MEN1 4455/4885MAOB 2490/4885 |
| US-20240293559-A1 | SHP2 inhibitor, pharmaceutical composition containing the same and application thereof | PTPN1, PTPN5, PTPN18 | KMT2A 2047/4885MEN1 1603/4885MAOB 3531/4885 |
| US-20020156295-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | THEM6, SOD1, SLC30A6 | KMT2A 2881/4885MEN1 1595/4885MAOB 967/4885 |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | KMT2A 1938/4885MEN1 688/4885MAOB 2905/4885 |
| US-12071445-B2 | Precatalyst scaffolds for cross-coupling reactions, and methods of making and using same | TIMCC, YAP1, TET2 | KMT2A 1597/4885MEN1 781/4885MAOB 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.